Helixgate https://validator.w3.org/feed/docs/rss2.html Drug Targets LDL Receptor Pathway to Control Cholesterol First-in-Human Stem Cell Therapy Trial for Huntington’s Disease Begins at UCI Health STAT+: Eli Lilly dives into hair loss treatments with investment in AI startup Absci Jubilant draws FDA rebuke for delayed mold investigation and quality unit lapses Judge temporarily blocks subpoenas in criminal probe of transgender care at New York hospitals Labs see rising demand for nitrosamine, topical performance and microbiome testing 10 companies hiring in San Francisco, South San Francisco (plus a few in Brisbane, San Rafael) Spurned by FDA, Passage Bio finds exit through merger with Remix Clinical trial set to test two drugs for fast-growing Ebola outbreak Novel Feeder Cell Line Dramatically Expands NK Cell Production Lonza and InduPro to collaborate on next-gen ADC therapies  Investors pour $115M into RQ Bio in search of a preventive flu drug STAT+: A dispatch on AI from BIOtech’s big summer bash REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy BIO CEO Crowley, DOD doctor Overton are top candidates for FDA commissioner: RBC STAT+: At BIO, a glimpse behind Lilly and Chai’s partnership Medra Launches Reasoning Layer for Drug Discovery Robotics Lilly deepens relationship with China’s Abbisko for $1.9B biobucks STAT+: Pharmalittle: We’re reading about an FDA commissioner candidate, Germany’s plans for drug prices, and more AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China Why South Africa’s leopards shrank to half their normal size STAT+: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval Takeda enters transitional year as new CEO seeks return to growth BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech Ollin parlays Vabysmo beat into $330M raise to test eye disease drug in Phase 3 Ollin refuels with $330M to back pivotal tests of Vabysmo challenger California Still Golden Despite Job Losses: Industry Group Opinion: New human embryo editing advances require tough conversations on ethical boundaries The most dangerous person in the company Big Pharma restructures to ride out ‘existential risk’ FDA uncertainty adds risk to biopharma deals Gene Editing Pioneer Sangamo Files for Chapter 11 Bankruptcy; Agrees to Sell Assets A Streptomyces megacluster encodes synergistic biotin-targeting antibiotics STAT+: FDA drops enforcement against Whoop after it tweaks blood pressure feature STAT+: Want high-quality generic drugs? One expert has ideas on how consumers can trust their supply Three Subtypes of Severe Pneumonia Might Inform Personalized Therapies Judge rules government can’t stop SNAP dollars from buying candy and sugary drinks Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering Pfizer drug acquired in Seagen deal disappoints in lung cancer study Cellares extends funding for cell therapy manufacturing  Texas doctor charged in $89M fraud case as administration pushes health care crackdown Scientists finally solved how H5N1 bird flu hid in dairy cows Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy STAT+: Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more STAT+: Exclusive: Mystery man gets experimental GLP-1 Discreet biotech Osanni Bio starts making noise with $190M series B for clinical push STAT+: Pharmalittle: We’re reading about FDA reforming clinical trials, a Pfizer setback, and much more news STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program Home